Trans-Institutional Work

The Leukemia Tissue Bank Shared Resource (LTBSR) serves as a central processing and storage laboratory for several multi-site trials in which the principal investigator is an OSUCCC member. These include: 

JH9815:A Pilot Study of ATRA + one cycle of timed sequential chemotherapy for the treatments of APL. (G. Marcucci, CoI)

OSU 9977: A phase I trial of G3139 in acute leukemia. (G. Marcucci , PI)

OSU 0163: An Open-label Phase II/III Study of Rituximab in Combination with Recombinant Human IL-2 (IL-2) for Relapsed Low-grade or Follicular Non-Hodgkin's Lymphoma in Subjects Who Have Previously Failed Rituximab. (P. Porcu, PI)

OSU 07028: A Phase II Simon Two-Stage Multicenter Study and Pilot Pharmacodynamic Investigation of GTI-2040 in Combination with High Dose Cytarabine (HiDAC) in Refractory and Relapsed Acute Myeloid Leukemia (AML). (R. Klisovic, PI)

OSU 08194: An Open-label, Dose-escalation, Phase I Study of IMC-EB10 in Patients with Relapsed or Refractory Acute Myeloid Leukemia. (W. Blum, PI)

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu